Skip to main navigation Skip to search Skip to main content

Investigation of (S)-(-)-acidomycin: A selective antimycobacterial natural product that inhibits biotin synthase

  • Matthew R. Bockman
  • , Curtis A. Engelhart
  • , Julia D. Cramer
  • , Michael D. Howe
  • , Neeraj K. Mishra
  • , Matthew Zimmerman
  • , Peter Larson
  • , Nadine Alvarez-Cabrera
  • , Sae Woong Park
  • , Helena I.M. Boshoff
  • , James M. Bean
  • , Victor G. Young
  • , David M. Ferguson
  • , Veronique Dartois
  • , Joseph T. Jarrett
  • , Dirk Schnappinger
  • , Courtney C. Aldrich
  • University of Minnesota Twin Cities
  • Cornell University
  • University of Hawai'i at Mānoa
  • National Institutes of Health
  • Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

The synthesis, absolute stereochemical configuration, complete biological characterization, mechanism of action and resistance, and pharmacokinetic properties of (S)-(-)-acidomycin are described. Acidomycin possesses promising antitubercular activity against a series of contemporary drug susceptible and drug-resistant M. tuberculosis strains (minimum inhibitory concentrations (MICs) = 0.096-6.2 μM) but is inactive against nontuberculosis mycobacteria and Gram-positive and Gram-negative pathogens (MICs > 1000 μM). Complementation studies with biotin biosynthetic pathway intermediates and subsequent biochemical studies confirmed acidomycin inhibits biotin synthesis with a K i of approximately 1 μM through the competitive inhibition of biotin synthase (BioB) and also stimulates unproductive cleavage of S-adenosyl-l-methionine (SAM) to generate the toxic metabolite 5′-deoxyadenosine. Cell studies demonstrate acidomycin selectively accumulates in M. tuberculosis providing a mechanistic basis for the observed antibacterial activity. The development of spontaneous resistance by M. tuberculosis to acidomycin was difficult, and only low-level resistance to acidomycin was observed by overexpression of BioB. Collectively, the results provide a foundation to advance acidomycin and highlight BioB as a promising target.

Original languageEnglish
Pages (from-to)598-617
Number of pages20
JournalACS Infectious Diseases
Volume5
Issue number4
DOIs
StatePublished - 12 Apr 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Mycobacterium tuberculosis
  • accumulation
  • acidomycin
  • antimetabolite
  • biotin biosynthesis
  • biotin synthase
  • tuberculosis

Fingerprint

Dive into the research topics of 'Investigation of (S)-(-)-acidomycin: A selective antimycobacterial natural product that inhibits biotin synthase'. Together they form a unique fingerprint.

Cite this